ERBB2 and breast cancer: Guidelines were set for neoadjuvant treatment of all stage II-III BC together with other stages of the aggressive triple negative (TN) and human epidermal growth factor receptor (HER2)-positive subtypes and is still routine clinical practice until this date (5, 6).